Parkinson's Breakthrough Reveals Protein Mutation's Role in Easing Cellular Traffic Jams

Study finds LRRK2 mutation can alleviate alpha-synuclein-induced congestion in neurons, shedding light on Parkinson's progression.

Apr. 10, 2026 at 7:07pm

Got story updates? Submit your updates here. ›

A highly detailed, translucent X-ray-style photograph showing the intricate internal structure of a neuron, with glowing ghostly lines representing the cellular transport system partially obscured by a dense, shadowy mass symbolizing Parkinson's-related Lewy bodies, conveying the complex interplay between proteins that can disrupt or restore normal cellular function.An X-ray-like view into the inner workings of a neuron, revealing the delicate balance between proteins that can either facilitate or obstruct cellular transport, a key factor in the progression of Parkinson's disease.Buffalo Today

In a groundbreaking discovery, researchers have found that a mutation in the LRRK2 protein can alleviate the cellular congestion caused by the Parkinson's-related protein alpha-synuclein. This research sheds light on the intricate relationship between these two proteins and their role in the progression of Parkinson's disease.

Why it matters

Parkinson's disease is characterized by the buildup of Lewy bodies, which are clumps of the alpha-synuclein protein. These clumps are the result of alpha-synuclein interfering with the transport system within neurons, causing cellular traffic jams. Understanding how to unclog these jams and restore normal cellular function is crucial for developing new treatments for Parkinson's.

The details

Researchers from the University at Buffalo discovered that by manipulating the interaction between alpha-synuclein and the Parkinson's-related protein LRRK2, they could restore normal axonal transport. Specifically, they found that increasing the levels of a specific mutant form of LRRK2 reduced alpha-synuclein's ability to bind to cargo and disrupt axonal transport, effectively alleviating the cellular traffic jams.

  • The study was published in April 2026.

The players

Dr. Shermali Gunawardena

The lead author of the study and a researcher at the University at Buffalo.

Piyali Chakraborty

A member of the research team at the University at Buffalo.

Pratima Bajgain

A member of the research team at the University at Buffalo.

Jing Huang

A member of the research team at the University at Buffalo.

Rakibul Islam

A member of the research team at the University at Buffalo.

Rupkatha Banerjee

A member of the research team at the University at Buffalo.

Got photos? Submit your photos here. ›

What they’re saying

“The proteins alpha-synuclein and LRRK2 must work in harmony, and any imbalance can lead to axonal transport issues.”

— Dr. Shermali Gunawardena, Lead author of the study

“Understanding the diverse functions of these genes is challenging, but by uncovering a link between two of them, we've taken a step towards unraveling the early stages of Parkinson's.”

— Dr. Shermali Gunawardena, Lead author of the study

What’s next

The researchers plan to further investigate the impact of the LRRK2 mutations on Lewy body formation and neuronal cell death, as the current study did not find a direct link between the improved axonal transport and these outcomes. Additionally, they will explore the potential for targeting the LRRK2-alpha-synuclein interaction as a therapeutic intervention for Parkinson's disease.

The takeaway

This study provides valuable insights into the complex interplay between Parkinson's-related proteins and their role in the disease's progression. By uncovering a functional connection between SNCA and LRRK2, the researchers have taken an important step towards unraveling the early stages of Parkinson's and identifying potential new avenues for treatment.